建立有限采样法估算天疱疮口服霉酚酸酯血药浓度-时间曲线下面积的模型

Abstract
Figure/Table
References (24)
Related Citation (1)

Download: PDF (0 KB) HTML (48 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objectives To investigate the establishment of area of limited sampling strategies for the estimation of Mycophenolic acid area under the concentration-time curve (AUC) in pemphigus patients.Methods The peripheral venous blood of 28 patients with pemphigus admitted into our hospital from October 2016 to December 2018 were collected before taking MMF and after taking MMF at 0.5,1,2,4,6,8 and 12 h.The concentration of mycophenolic acid (MPA) in plasma was measured by enzyme amplification immunoassay (EMIT).The MPA-AUC was calculated by linear trapezoid method at 0-12 h after administration.The regression equation and correlation coefficient of MPA-AUC 0-12h were estimated by SPSS software,and the accuracy of the model was evaluated by prediction error.Results A total of 28 patients with pemphigus had the same shape of MPA blood concentration time curve.Among them,the complex correlation coefficient of 1 point and 2 point fitting was lower,and the complex correlation coefficient of 3-5 point fitting was higher.A total of 9 models with high complex correlation coefficient were selected,among which the accuracy of model 3 to model 9 was increased.Conclusion Considering the operability and cost of detection,it is recommended that the mathematical model of 3 and 4 points can be used to estimate the MPA-AUC 0-12h after taking MMF in pemphigus patients.

Key words： Limited sampling strategies Area under the concentration-time curve Pemphigus Mycophenolic acid

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Sheng-hong
	HE Wen-li

Cite this article:

GUO Sheng-hong,HE Wen-li. Establishment of area of limited sampling strategies for the estimation of Mycophenolic acid area under the concentration-time curve in pemphigus patients[J]. 中国当代医药, 2020, 27(14): 8-14.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I14/8

[3]	郭生红，李薇，夏登梅.单用泼尼松及联用吗替麦考酚酯、硫唑嘌呤治疗天疱疮近期临床观察[J].临床皮肤科杂志，2014，43（3）：143-147.
[4]	卢晓红，王培光.皮肌炎治疗研究进展[J].中国临床药理学与治疗学，2018，23（7）：836-840.
[1]	Bardsley-Elliot A，Noble S，Foster RH.Mycophenolate mofetil：a review of its use in the management of solid organ transplantation[J].Bio Drugs，1999，12（5）：363-410.
[2]	Eskin-Schwartz M，David M，Mimouni D.Mycophenolate mofetil for the management of autoimmune bullous diseases[J].Dermatol Clin，2011，29（4）：555-559.
[5]	鲁静浩，李明.系统性硬皮病相关间质性肺病的药物治疗进展[J].复旦学报（医学版），2018，45（5）：740-743，747.
[6]	Doukaki S，Pistone G，Aricò M，et al.Pharmacokinetic evaluation of mycophenolate mofetil for pemphigus[J].Expert Opin Drug Metab Toxicol，2011，7（2）：237-244.
[7]	Filler G，Mai I.Limited sampling strategy for mycophenolic acid area under the curve[J].Ther Drug Monit，2000，22（2）：169-173.
[8]	谢文慧，张卓莉.治疗药物监测在系统性红斑狼疮治疗中的研究现状[J].中国临床药理学杂志，2019，35（1）：87-90.
[9]	曾维胜，李珍，宋秘，等.性别对肾移植受体霉酚酸血药浓度影响的临床分析[J].器官移植，2018，9（5）：385-389.
[10]	郭生红，邹远高，李薇，等.有限采样法估算天疱疮患者霉酚酸AUC 模型的建立[J].四川大学学报（医学版），2015，46（4）：633-637.
[11]	Harman KE，Brown D，Exton LS，et al.British association of dermatologists′ guidelines for the management of pemphigus vulgaris 2017[J].Br J Dermatol，2017，177（5）：1170-1201.
[12]	Cholera M，Chainani-Wu N.Management of pemphigus vulgaris[J].Adv Ther，2016，33（6）：910-958.
[13]	Witte M，Zillikens D，Schmidt E.Diagnosis of autoimmune blistering diseases[J].Front Med，2018，5（1）：296.
[14]	Murrell DF，Pena S，Joly P，et al.Diagnosis and management of pemphigus：recom mendations by an international panel of experts[J].J Am Acad Dermatol，2018，2（21）：S019096221830207X.
[15]	Beissert S，Mimouni D，Kanwar AJ，et al.Treating pemphigus vulgaris with prednisone and mycophenolate mofetil：a multicenter，randomized，placebo-controlled trial[J].J Invest Dermatol，2010，130（8）：2041-2048.
[16]	Baskan EB，Yilmaz M，Tunali S，et al.Efficacy and safety of long-term mycophenolate sodium therapy in pemphigus vulgaris[J].J Eur Acad Dermatol Venereol，2009，23（12）：1432-1434.
[17]	Esmaili N，Chams-Davatchi C，Valikhani M，et al.Treatment of pemphigus vulgaris with mycophenolate mofetil as a steroid-sparing agent[J].Eur J Dermatol，2008，18（2）：159-164.
[18]	Zwerner J，Fiorentino D.Mycophenolate mofetil[J].Dermatol Ther，2007，20（4）：229-238.
[19]	张致庆.基因多态性对儿童霉酚酸酯个体化治疗的意义[J].临床儿科杂志，2018，36（5）：384-388.
[20]	Brenda CM，van Gelder T，Ron AA，et al.Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after entericcoated mycophenolate sodium[J].Ther Drug Monit，2009，31（5）：585-591.
[21]	杨冬爱，陈琳琳.治疗药物监测的方法学研究进展[J].中国医药科学，2016，6（8）：38-40，113.
[22]	李纳，朱振峰，丰贵文，等.有限采样法估算麦考酚钠药-时曲线下面积及其药动学[J].医药导报，2016，35（11）：1177-1180.
[23]	Katherine A，Nicole M，Michael E，et al.Evaluation of limited sampling strategies for mycophenolic acid after mycophenolate mofetil intake in adult kidney transplant recipients[J].Ther Drug Monit，2010，32（6）：723-733.
[24]	Dickinson L，Back D，Posniak A，et al.Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus infected individuals[J].Ther Drug Monit，2007，29（3）：361-367.